Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss M, Heppt F, Meder C, Atreya R, Klenske E, Dietrich P, Abdullah A, Kliem T, Corte G, Morf H, Leppkes M, Kremer A, Pachowsky M, Schuch F, Ronneberger M, Kleinert S, Meier C, Hueber A, Manger K, Manger B, Berking C, Tenbusch M, Überla K, Sticherling M, Neurath M, Schett G, Ramming A (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Nature Communications Nature Publishing Group: Nature Communications

Book Volume: 11

Article Number: 3774

Journal Issue: 1

DOI: 10.1038/s41467-020-17703-6

Abstract

Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.

Authors with CRIS profile

David Simon Department of Medicine 3 – Rheumatology and Immunology Gerhard Krönke Department of Medicine 3 – Rheumatology and Immunology Arnd Kleyer Department of Medicine 3 – Rheumatology and Immunology Mario Zaiss Department of Medicine 3 – Rheumatology and Immunology Franz Heppt Department of Dermatology Christine Meder Department of Dermatology Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur) Peter Dietrich Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Andreas Kremer Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Milena Pachowsky Department of Medicine 3 – Rheumatology and Immunology Axel Hueber Department of Medicine 3 – Rheumatology and Immunology Karin Manger Medizinische Fakultät Bernhard Manger Professur für Rheumatologie und Klinische Immunologie Carola Berking Lehrstuhl für Haut- und Geschlechtskrankheiten Matthias Tenbusch Professur für Genbasierte Immunisierungsverfahren Klaus Überla Lehrstuhl für Klinische und Molekulare Virologie Michael Sticherling Professur für Dermatologie Markus Neurath Lehrstuhl für Innere Medizin I Georg Schett Lehrstuhl für Innere Medizin III Andreas Ramming Department of Medicine 3 – Rheumatology and Immunology

Additional Organisation(s)

Interdisziplinäres Zentrum für Klinische Forschung

Related research project(s)

D032: The role of neuropeptide Y in chemo-resistance and immune checkpoint inhibition in hepatocellular carcinoma March 1, 2020 - Feb. 28, 2023

How to cite

APA:

Simon, D., Tascilar, K., Krönke, G., Kleyer, A., Zaiss, M., Heppt, F.,... Ramming, A. (2020). Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nature Communications, 11(1). https://doi.org/10.1038/s41467-020-17703-6

MLA:

Simon, David, et al. "Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion." Nature Communications 11.1 (2020).

BibTeX: Download